Brainstorm Health: Sangamo Stock, FDA Walgreens Warning, DNA Malware [Fortune]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Fortune
Brainstorm Health: Sangamo Stock, FDA Walgreens Warning, DNA Malware By Sy Mukherjee February 7, 2019 Greetings, readers. Gene therapy and gene editing have taken the life sciences by storm in the past few years. We’ve seen the approvals of treatments that re-engineer patients’ cells to fight cancer and shocking claims of gene-edited babies abroad; dozens of biotechs continue to experiment with technologies such as CRISPR and “gene silencing,” techniques which could (theoretically) curb a multitude of diseases, from rare inherited disorders to cancers. But the sector had a dour day as a pair of early-stage studies came up short. Sangamo Therapeutics stock sank 31% in Thursday trading on interim data for gene-editing techniques to treat the rare disorders MPS I and II. It’s a particularly unfortunate setback since the news wasn’t all bad. The underlying technology actually did In another part of the sector, Solid Biosciences’ gene therapy treatment for the devastating movement disorder
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingBusiness Wire
- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, up previously from $3.00.MarketBeat
- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
SGMO
Earnings
- 3/13/24 - Miss
SGMO
Sec Filings
- 3/25/24 - Form 8-K
- 3/25/24 - Form 424B5
- 3/13/24 - Form 8-K
- SGMO's page on the SEC website